Bristol Myers Squibb has won Food and Drug Administration fast-track designation for its BMS-986446 drug candidate in Alzheimer's disease. Bristol Myers on Wednesday said BMS-986446 is a potential ...
All of the DTC channels offer discounts for people willing and able to pay for medicines with cash, and that also applies to ...
BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease ...
The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it ...
US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...
US pharma major Bristol Myers Squibb has announced an expansion of its direct-to-patient offerings, providing eligible US ...
[Editor’s note: The hacker requested that we remove the image for legal reasons, so it’s blurry now. We hope all’s well!] Lithium technology has ushered in a new era of batteries with exceptionally ...
Stephan Simon – formerly head of warranty & indemnity (W&I) in the private equity, M&A and tax division at BMS Group – is set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback